BioSpace News Archive

Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, provided an organizational update outlining key objectives toward advancing the development of its lead targeted oncology assets, IK-930 and IK-595.

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-targeting antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (uHCC).

Korro Bio, Inc. presented new data for KRRO-110 and reported progress across its RNA editing portfolio at the J.P. Morgan Healthcare Conference on January 9, 2024.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced that the newly established Queensland Spatial Biology Centre, located in Brisbane, Australia, is using the PhenoCycler-Fusion spatial biology platform as the core technology to revolutionize the way cancer and other debilitating diseases are diagnosed and treated.

Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines, announced a collaboration with the University of Central Florida to advance space medicine research.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, Gordon Silver Limited and Verity Pharmaceuticals, Inc. (Verity Pharma) today announced that they have entered into an exclusive licensing agreement under which Verity Pharma will market TLANDO® in the United States and, if approved, in Canada.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) today announced positive pre-clinical safety data of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in combination with sitagliptin, a DPP4 inhibitor.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis, announced that James Leech has joined the company as Chief Financial and Strategy Officer.

Kallisio, focused on developing solutions to manage toxicity in cancer care, announces FDA 510(k) clearance for Stentra, an individually tailored 3D printed oral stent solution designed to protect healthy tissue in Head and Neck Cancer (HNC) patients.

iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will be participating in the Maxim Group Virtual Healthcare IT Conference on January 25, 2024.